Reviewing CERo Therapeutics (CERO) and Its Peers

CERo Therapeutics (NASDAQ:CERO) is one of 248 publicly-traded companies in the “MED – DRUGS” industry, but how does it weigh in compared to its competitors? We will compare CERo Therapeutics to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, dividends, earnings, valuation and risk.

Profitability

This table compares CERo Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
CERo Therapeutics Competitors	-21,934.00%	-158.76%	-18.03%

Volatility & Risk

CERo Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, CERo Therapeutics’ competitors have a beta of 1.27, meaning that their average share price is 27% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for CERo Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1	3	0	0	1.75
CERo Therapeutics Competitors	2065	3751	9785	403	2.53

CERo Therapeutics currently has a consensus target price of $45.00, suggesting a potential upside of 68,081.82%. As a group, “MED – DRUGS” companies have a potential upside of 59.04%. Given CERo Therapeutics’ higher possible upside, equities research analysts clearly believe CERo Therapeutics is more favorable than its competitors.

Valuation and Earnings

This table compares CERo Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
CERo Therapeutics	N/A	-$8.30 million	0.00
CERo Therapeutics Competitors	$30.16 billion	$57.22 million	3.57

CERo Therapeutics’ competitors have higher revenue and earnings than CERo Therapeutics. CERo Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

29.6% of CERo Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of shares of all “MED – DRUGS” companies are owned by institutional investors. 12.7% of CERo Therapeutics shares are owned by company insiders. Comparatively, 13.4% of shares of all “MED – DRUGS” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

CERo Therapeutics competitors beat CERo Therapeutics on 10 of the 13 factors compared.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.